The Role of Exosomes in Pancreatic Cancer

Lan, Bin; Zeng, Siyuan; Grützmann, Robert; Pilarsky, Christian

doi:10.3390/ijms20184332

Cited by 58 publications

(53 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unfortunately, most of the patients with pancreatic cancer fail to develop important symptoms before reaching the advanced stage of the disease. Moreover, the CA19-9 antigen test, currently in use, is not sufficient to diagnose pancreatic cancer with high sensitivity and specificity [3]. According to GLOBOCAN data, 458,918 new cases of pancreatic cancer and 432,242 new deaths were recorded in 2018.…”

Section: Introductionmentioning

confidence: 99%

CD36 and CD97 in Pancreatic Cancer versus Other Malignancies

Tănase

Gheorghișan-Gălățeanu

Popescu

et al. 2020

IJMS

View full text Add to dashboard Cite

Starting from the recent identification of CD36 and CD97 as a novel marker combination of fibroblast quiescence in lung during fibrosis, we aimed to survey the literature in search for facts about the separate (or concomitant) expression of clusters of differentiation CD36 and CD97 in either tumor- or pancreatic-cancer-associated cells. Here, we provide an account of the current knowledge on the diversity of the cellular functions of CD36 and CD97 and explore their potential (common) contributions to key cellular events in oncogenesis or metastasis development. Emphasis is placed on quiescence as an underexplored mechanism and/or potential target in therapy. Furthermore, we discuss intricate signaling mechanisms and networks involving CD36 and CD97 that may regulate different subpopulations of tumor-associated cells, such as cancer-associated fibroblasts, adipocyte-associated fibroblasts, tumor-associated macrophages, or neutrophils, during aggressive pancreatic cancer. The coexistence of quiescence and activated states in cancer-associated cell subtypes during pancreatic cancer should be better documented, in different histological forms. Remodeling of the local microenvironment may also change the balance between growth and dormant state. Taking advantage of the reported data in different other tissue types, we explore the possibility to induce quiescence (similar to that observed in normal cells), as a therapeutic option to delay the currently observed clinical outcome.

show abstract

Section: Introductionmentioning

confidence: 99%

CD36 and CD97 in Pancreatic Cancer versus Other Malignancies

Tănase

Gheorghișan-Gălățeanu

Popescu

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Exosomes are potential communicative vectors which are important in the progression of human cancers, including pancreatic cancer. 41,42 Grimolizzi et al reported that exosomes from patients with NSCLC could induce malignant transformation in epithelial cells. 43 Wei et al indicated that gastric cancer cell-derived exosomal miR-15b-3p led to the malignant transformation of gastric mucosa epithelium cells, promoting cell proliferation and migration.…”

mentioning

confidence: 99%

<p>Hsa_circ_0000069 Knockdown Inhibits Tumorigenesis and Exosomes with Downregulated hsa_circ_0000069 Suppress Malignant Transformation via Inhibition of STIL in Pancreatic Cancer</p>

Ye¹,

Zhu²,

Xie³

et al. 2020

IJN

View full text Add to dashboard Cite

“… 34 , 35 Many studies have demonstrated that exosome could be used as diagnostic biomarker for PDAC. 12 , 13 , 36 In addition, some studies have reported that exosomal miRNA can improve the accuracy of cancer detection. 28 , 37 , 38 Xu et al 39 show that plasma exosome miR-196a and miR-1246 are two potential indicators of localized pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Exosomal miRNA from pancreatic cancer cells may promote invasion and metastasis or chemoresistance, such as miRNA-222 and miRNA-155. 36 In the present study, we also performed in vitro study to test the role of miRNA-1226-3p on biological behaviors of PDAC. Interestingly, we found that high level of miRNA-1226-3p expression could inhibit PANC-1 and BXP-3 cell viability, promoted cell apoptosis and inhibit cell migration.…”

Section: Discussionmentioning

confidence: 99%

Serum Exosomal miRNA-1226 as Potential Biomarker of Pancreatic Ductal Adenocarcinoma

Wang¹,

Wang²,

Cui³

et al. 2021

OTT

View full text Add to dashboard Cite

Background Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related mortality and it is urgent to find biomarkers for early detection of PDAC. Exosomal miRNAs are useful biomarkers for cancer detection. The aims of this study were to investigate the potential role of serum exosomal miRNA in detection of PDAC and to analyze the correlation between the levels of exosome miRNA and the tumor biological behaviors. Materials and Methods Thirteen serum samples were collected from five patients with PDACs, three healthy individuals (HIs) and five benign pancreatic lesions (BP) for a high throughput profiling analysis to identify an altered miRNA expression patterns in PDAC. Candidate exosomal miRNAs were filtered based on a second independent cohort that included 17 PDACs and 12 benign pancreatic lesions by quantitative real-time polymerase chain reaction (qRT-PCR). Four miRNAs were selected for miRNA validation as PDAC biomarkers in a subsequent set of samples. The association between candidate exosomal miRNA and tumor behavior (tumor invasion or metastases) was evaluated in 17 PDACs. In vitro studies were performed to evaluate the role of candidate exosomal miRNA on cell viability, apoptosis and cell migration in two PDAC cell lines. Results The expression of 11 miRNAs showed same trend between PDAC and BP, and between PDAC and HIs. Six of them were upregulated (miR-203b-5p, miR-342-5p, miR-337-5p, miR-149-5p, miR-877-5p, miR-203a-3p), and five were downregulated (miR-1226-3p, miR-3182, miR-625-3p, miR-624-5p, miR-664a-5p). miR-1226-3p was selected as the candidate exosomal biomarker for the PDAC detection. The expression of serum exosomal miRNA-1226-3p was downregulated in PDACs compared to the BPs (p = 0.025). miR-1226-3p had acceptable performance in predicting [area under the curve (AUC) = 0.74] PDAC. Exosomal miRNA-1226-3p level in PDAC with invasion or metastases was lower than that without invasion or metastases (p = 0.028). Transfection of miRNA-1226-3p significantly inhibited the proliferation of PANC-1 and BXP-3 cells, stimulated cell apoptosis and inhibited cell migration. Conclusion Serum exosomal miRNA-1226-3p is a potential biomarker in diagnosing and predicting the tumor invasion or metastases of PDAC.

show abstract

The Role of Exosomes in Pancreatic Cancer

Cited by 58 publications

References 88 publications

CD36 and CD97 in Pancreatic Cancer versus Other Malignancies

CD36 and CD97 in Pancreatic Cancer versus Other Malignancies

<p>Hsa_circ_0000069 Knockdown Inhibits Tumorigenesis and Exosomes with Downregulated hsa_circ_0000069 Suppress Malignant Transformation via Inhibition of STIL in Pancreatic Cancer</p>

Serum Exosomal miRNA-1226 as Potential Biomarker of Pancreatic Ductal Adenocarcinoma

Contact Info

Product

Resources

About